REGENERON PHARMACEUTICALS (1REGN.MI) Fundamental Analysis & Valuation

BIT:1REGN • US75886F1075

Current stock price

667.6 EUR
+39.4 (+6.27%)
Last:

This 1REGN.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. 1REGN.MI Profitability Analysis

1.1 Basic Checks

  • In the past year 1REGN was profitable.
  • In the past year 1REGN had a positive cash flow from operations.
  • In the past 5 years 1REGN has always been profitable.
  • Each year in the past 5 years 1REGN had a positive operating cash flow.
1REGN.MI Yearly Net Income VS EBIT VS OCF VS FCF1REGN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 11.11%, 1REGN belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
  • With an excellent Return On Equity value of 14.41%, 1REGN belongs to the best of the industry, outperforming 87.65% of the companies in the same industry.
  • 1REGN has a Return On Invested Capital of 9.60%. This is amongst the best in the industry. 1REGN outperforms 85.19% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 1REGN is in line with the industry average of 10.61%.
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROIC 9.6%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.3%
ROIC(5y)18.08%
1REGN.MI Yearly ROA, ROE, ROIC1REGN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • 1REGN's Profit Margin of 31.41% is amongst the best of the industry. 1REGN outperforms 91.36% of its industry peers.
  • 1REGN's Profit Margin has declined in the last couple of years.
  • 1REGN has a better Operating Margin (27.02%) than 82.72% of its industry peers.
  • In the last couple of years the Operating Margin of 1REGN has declined.
  • The Gross Margin of 1REGN (86.56%) is better than 75.31% of its industry peers.
  • 1REGN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
1REGN.MI Yearly Profit, Operating, Gross Margins1REGN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. 1REGN.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1REGN is creating some value.
  • Compared to 1 year ago, 1REGN has less shares outstanding
  • The number of shares outstanding for 1REGN has been reduced compared to 5 years ago.
  • Compared to 1 year ago, 1REGN has an improved debt to assets ratio.
1REGN.MI Yearly Shares Outstanding1REGN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
1REGN.MI Yearly Total Debt VS Total Assets1REGN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • 1REGN has an Altman-Z score of 7.57. This indicates that 1REGN is financially healthy and has little risk of bankruptcy at the moment.
  • 1REGN has a better Altman-Z score (7.57) than 81.48% of its industry peers.
  • The Debt to FCF ratio of 1REGN is 0.72, which is an excellent value as it means it would take 1REGN, only 0.72 years of fcf income to pay off all of its debts.
  • 1REGN's Debt to FCF ratio of 0.72 is amongst the best of the industry. 1REGN outperforms 93.83% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that 1REGN is not too dependend on debt financing.
  • The Debt to Equity ratio of 1REGN (0.09) is better than 67.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Altman-Z 7.57
ROIC/WACC1.1
WACC8.75%
1REGN.MI Yearly LT Debt VS Equity VS FCF1REGN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • A Current Ratio of 4.13 indicates that 1REGN has no problem at all paying its short term obligations.
  • 1REGN has a better Current ratio (4.13) than 77.78% of its industry peers.
  • A Quick Ratio of 3.56 indicates that 1REGN has no problem at all paying its short term obligations.
  • 1REGN's Quick ratio of 3.56 is fine compared to the rest of the industry. 1REGN outperforms 75.31% of its industry peers.
Industry RankSector Rank
Current Ratio 4.13
Quick Ratio 3.56
1REGN.MI Yearly Current Assets VS Current Liabilites1REGN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. 1REGN.MI Growth Analysis

3.1 Past

  • 1REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.76%.
  • The Earnings Per Share has been growing slightly by 6.99% on average over the past years.
  • The Revenue has been growing slightly by 0.99% in the past year.
  • 1REGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.04% yearly.
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%

3.2 Future

  • 1REGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.96% yearly.
  • The Revenue is expected to grow by 8.10% on average over the next years. This is quite good.
EPS Next Y5.35%
EPS Next 2Y11.15%
EPS Next 3Y11.8%
EPS Next 5Y10.96%
Revenue Next Year10.55%
Revenue Next 2Y10.43%
Revenue Next 3Y9.77%
Revenue Next 5Y8.1%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1REGN.MI Yearly Revenue VS Estimates1REGN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
1REGN.MI Yearly EPS VS Estimates1REGN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20 40 60 80

More info and screens

Find the best growth stocksShow best growing peers

6

4. 1REGN.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 17.38, 1REGN is valued on the expensive side.
  • 1REGN's Price/Earnings ratio is rather cheap when compared to the industry. 1REGN is cheaper than 85.19% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of 1REGN to the average of the S&P500 Index (25.61), we can say 1REGN is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 16.50 indicates a correct valuation of 1REGN.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of 1REGN indicates a rather cheap valuation: 1REGN is cheaper than 86.42% of the companies listed in the same industry.
  • 1REGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.79.
Industry RankSector Rank
PE 17.38
Fwd PE 16.5
1REGN.MI Price Earnings VS Forward Price Earnings1REGN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 82.72% of the companies in the same industry are more expensive than 1REGN, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, 1REGN is valued cheaper than 85.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF 21.66
EV/EBITDA 12.32
1REGN.MI Per share data1REGN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of 1REGN may justify a higher PE ratio.
PEG (NY)3.25
PEG (5Y)2.48
EPS Next 2Y11.15%
EPS Next 3Y11.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. 1REGN.MI Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.51%, 1REGN is not a good candidate for dividend investing.
  • 1REGN's Dividend Yield is rather good when compared to the industry average which is at 0.64. 1REGN pays more dividend than 93.83% of the companies in the same industry.
  • With a Dividend Yield of 0.51, 1REGN pays less dividend than the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 0.51%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 1REGN pays out 8.22% of its income as dividend. This is a sustainable payout ratio.
DP8.22%
EPS Next 2Y11.15%
EPS Next 3Y11.8%
1REGN.MI Yearly Income VS Free CF VS Dividend1REGN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
1REGN.MI Dividend Payout.1REGN.MI Dividend Payout, showing the Payout Ratio.1REGN.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

1REGN.MI Fundamentals: All Metrics, Ratios and Statistics

REGENERON PHARMACEUTICALS

BIT:1REGN (3/10/2026, 7:00:00 PM)

667.6

+39.4 (+6.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30
Earnings (Next)04-27
Inst Owners90.78%
Inst Owner ChangeN/A
Ins Owners1.94%
Ins Owner ChangeN/A
Market Cap70.58B
Revenue(TTM)14.34B
Net Income(TTM)4.50B
Analysts81.11
Price Target726.78 (8.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.51%
Yearly Dividend2.98
Dividend Growth(5Y)N/A
DP8.22%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.31%
Min EPS beat(2)5.66%
Max EPS beat(2)20.96%
EPS beat(4)3
Avg EPS beat(4)16.93%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.59%
EPS beat(12)10
Avg EPS beat(12)8.05%
EPS beat(16)13
Avg EPS beat(16)8.3%
Revenue beat(2)2
Avg Revenue beat(2)1.44%
Min Revenue beat(2)0.21%
Max Revenue beat(2)2.66%
Revenue beat(4)3
Avg Revenue beat(4)0.82%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.06%
Revenue beat(12)8
Avg Revenue beat(12)0.91%
Revenue beat(16)12
Avg Revenue beat(16)1.57%
PT rev (1m)9.16%
PT rev (3m)9.16%
EPS NQ rev (1m)-12.9%
EPS NQ rev (3m)-12.9%
EPS NY rev (1m)1.5%
EPS NY rev (3m)1.5%
Revenue NQ rev (1m)0.4%
Revenue NQ rev (3m)0.4%
Revenue NY rev (1m)3.85%
Revenue NY rev (3m)3.85%
Valuation
Industry RankSector Rank
PE 17.38
Fwd PE 16.5
P/S 5.69
P/FCF 21.66
P/OCF 16.38
P/B 2.61
P/tB 2.72
EV/EBITDA 12.32
EPS(TTM)38.41
EY5.75%
EPS(NY)40.46
Fwd EY6.06%
FCF(TTM)30.82
FCFY4.62%
OCF(TTM)40.76
OCFY6.11%
SpS117.41
BVpS255.87
TBVpS245.58
PEG (NY)3.25
PEG (5Y)2.48
Graham Number470.24
Profitability
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROCE 10.71%
ROIC 9.6%
ROICexc 29.34%
ROICexgc 32.83%
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
FCFM 26.25%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.3%
ROIC(5y)18.08%
ROICexc(3y)21.75%
ROICexc(5y)28.65%
ROICexgc(3y)23.56%
ROICexgc(5y)30%
ROCE(3y)12.6%
ROCE(5y)20.17%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y2.24%
ROICexc growth 3Y4.54%
ROICexc growth 5Y-0.03%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Debt/EBITDA 0.61
Cap/Depr 223.23%
Cap/Sales 8.46%
Interest Coverage 93.15
Cash Conversion 112.68%
Profit Quality 83.58%
Current Ratio 4.13
Quick Ratio 3.56
Altman-Z 7.57
F-Score5
WACC8.75%
ROIC/WACC1.1
Cap/Depr(3y)208.61%
Cap/Depr(5y)258.46%
Cap/Sales(3y)7.24%
Cap/Sales(5y)7.69%
Profit Quality(3y)85.52%
Profit Quality(5y)83.15%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
EPS Next Y5.35%
EPS Next 2Y11.15%
EPS Next 3Y11.8%
EPS Next 5Y10.96%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%
Revenue Next Year10.55%
Revenue Next 2Y10.43%
Revenue Next 3Y9.77%
Revenue Next 5Y8.1%
EBIT growth 1Y-8.13%
EBIT growth 3Y-9.64%
EBIT growth 5Y1.67%
EBIT Next Year13.49%
EBIT Next 3Y14.31%
EBIT Next 5Y10.45%
FCF growth 1Y6.39%
FCF growth 3Y3.48%
FCF growth 5Y13.45%
OCF growth 1Y12.63%
OCF growth 3Y-0.24%
OCF growth 5Y13.72%

REGENERON PHARMACEUTICALS / 1REGN.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 7 / 10 to 1REGN.MI.


What is the valuation status of REGENERON PHARMACEUTICALS (1REGN.MI) stock?

ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (1REGN.MI). This can be considered as Fairly Valued.


What is the profitability of 1REGN stock?

REGENERON PHARMACEUTICALS (1REGN.MI) has a profitability rating of 7 / 10.


What are the PE and PB ratios of REGENERON PHARMACEUTICALS (1REGN.MI) stock?

The Price/Earnings (PE) ratio for REGENERON PHARMACEUTICALS (1REGN.MI) is 17.38 and the Price/Book (PB) ratio is 2.61.


What is the expected EPS growth for REGENERON PHARMACEUTICALS (1REGN.MI) stock?

The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (1REGN.MI) is expected to grow by 5.35% in the next year.